Another promising EZH2 inhibitor, GSK343, also selectively inhibits H3K27 methylation and has shown efficacy in reactivating silenced tumor-suppressor genes, particularly in cancers with EZH2 mutations or overexpression. This evidence concerns the gene EZH2 and neoplasm.